Overview: Molecular Screening (HBB) TestIntroduction: The Molecular Screening (HBB) Test tests for HBB gene mutations to diagnose thalassemia or sickle cell disease, causing anemia or pain crises, aiding in genetic diagnosis. Affecting 1 in 100,000 people with thalassemia, HBB mutations pose diagnostic challenges due to ethnic variation. Following 2023 American Society of Hematology (ASH) guidelines, it uses PCR/sequencing for high accuracy, supporting molecular pathology screening. This test is vital for diagnosis, genetic counseling, and improving outcomes in hematology.
Other Names: HBB Gene Test, Thalassemia/Sickle Cell Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: HBB mutation testing began in the 1980s with research by Kan, who identified the gene. PCR/sequencing advancements by Illumina improved detection, surpassing earlier restriction analysis.
Purpose: Detects HBB mutations to diagnose thalassemia or sickle cell disease, guides transfusion or hydroxyurea therapy, and evaluates patients with anemia, aiming to manage disease.
Test Parameters: HBB mutation status
Pretest Condition: No special preparation required. Collect whole blood, buccal swab, or saliva. Report history of anemia.
Specimen: Whole Blood (EDTA, 3-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document anemia or pain crises. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., stroke), and sample collection risks.
Procedural Considerations: Uses PCR/sequencing to detect mutations, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive mutation confirms thalassemia or sickle cell disease, guiding therapy. Early management might prevent complications, while untreated cases lead to death. Normal results may require hemoglobin electrophoresis.
Specialist Consultation: Consult a hematologist or genetic counselor for interpretation.
Additional Supporting Tests: Hemoglobin electrophoresis, CBC, or genetic panel to confirm diagnosis.
Test Limitations: Specific to HBB; correlation with clinical status needed. False negatives possible with untested variants.
References: ASH Guidelines, 2023; Blood, Kan YW, 2022.
